New research published in Lab on a Chip demonstrates 100x sensitivity improvement on Simoa; marks significant advancement in sensitivity for industry leading detection platform Quanterix has pioneered ...

Findings by leading researchers demonstrate the promise and relevance of Simoa in vast application areas BILLERICA, Mass.--(BUSINESS WIRE)-- Quanterix Corporation (NASDAQ: QTRX), a company digitizing ...

The Simoa Disc is the first diagnostic developed using Sony DADC's optical disc manufacturing technology; will be used in Simoa technology to improve testing quality in life science research LEXINGTON ...

Quanterix Corporation, developer of the Single Molecule Array (Simoa) technology, announced today that it had been issued a US Patent for ultra-sensitive detection of molecules. The patent issue marks ...

BILLERICA, Mass., April 01, 2025--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced the ...

Companies expect to launch a product for the life sci market by 2013 and for the IVD segment by 2014. Stratec Biomedical has agreed to co-develop and manufacture a full automated version of Quanterix’ ...

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that its ultra-sensitive ...

LEXINGTON, Mass. Quanterix Corporation, a leader in high definition diagnostics, today announced that The Journal of Clinical Chemistry has published a new study in which its single molecule array ...

The devastation of a brain injury can be obvious. Sometimes. Yet other times, the extent of a traumatic injury is much more difficult to evaluate and quantify. This is particularly the case for mild ...

Quanterix Corporation, a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that its Simoa ® technology has powered important advances in ongoing clinical ...